^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy

Excerpt:
A 59-yr-old male presented clinically with abdominal pain and fullness...Surgical pathology confirmed intrahepatic cholangiocarcinoma, which was staged as T2aN0...the patient underwent a repeat tumor biopsy and RNA profiling of his cancer using an NGS assay, OSU-SpARKFuse (Reeser et al. 2017), which revealed a novel gene fusion involving FGFR2 (exons 1–16) and CLIP1 (exons 19–24)...After a total of 5 mo (7 cycles) on INCB054828, CT scans showed a 41.3% increase in size of the two target lesions confirming progressive disease...
DOI:
https://dx.doi.org/10.1101%2Fmcs.a004002